Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy

Lea Veijola, Eveliina Myllyluoma, Riitta Korpela, Hilpi Rautelin

AIM: To evaluate two enzyme immunoassay-based stool antigen tests, Premier Platinum HpSA and Amplified IDEIA HpStAR, and one rapid test, ImmunoCard STAT! HpSA, in the primary diagnosis of Helicobacter pylori (H. pylori) infection and after eradication therapy.

METHODS: Altogether 1,574 adult subjects were screened with a whole-blood H pylori antibody test and positive results were confirmed with locally validated serology and 14C-urea breath test. All 185 subjects, confirmed to be H pylori positive, and 97 H pylori-negative individuals, randomly selected from the screened study population and with negative results in serology and UBT, were enrolled. After eradication therapy the results of 182 subjects were assessed.

RESULTS: At baseline, the sensitivity of HpSA and HpStAR was 91.9% and 96.2%, respectively, and specificity was 95.9% for both tests. ImmunoCard had sensitivity of 93.0% but specificity of only 88.7%. After eradication therapy, HpSA and HpStAR had sensitivity of 81.3% and 100%, and specificity of 97.0% and 97.6%, respectively. ImmunoCard had sensitivity of 93.8% and specificity of 97.0%. HpSA, HpStAR, and ImmunoCard had PPV 77%, 80%, and 75%, and NPV 98%, 100%, and 99%, respectively.

CONCLUSION: In primary diagnosis, the EIA-based tests performed well. After eradication therapy, negative results were highly accurate for all the three tests. HpStAR had the best overall performance.

Key words: Diagnosis; Feces; Helicobacter pylori; Therapy

INTRODUCTION

H pylori infection is one of the most common infections in human beings worldwide, strongly associated with peptic ulcer disease and gastric cancer[3-4]. There are several methods available to detect H pylori infection including invasive methods based on gastric biopsies and non-invasive methods like serology, urea breath tests (UBTs), and stool antigen tests[3-4]. Stool antigen tests have recently been welcomed with great expectations as they are convenient to the patients and can be easily performed even in small laboratories[5-6]. However, the accuracy of stool antigen tests in different clinical situations and outside of controlled studies is a matter of concern[6-9].

Several commercial stool antigen tests are available: enzyme immunoassays (EIAs) based on either polyclonal (Premier Platinum HpSA, Meridian Inc., Cincinnati, OH, USA) or mAbs (Amplified IDEIA HpStAR, also known as Femtolab, Dako, Glostrup, Denmark) and rapid bed-side tests like ImmunoCard STAT! HpSA (Meridian Bioscience Europe, Milan, Italy). HpSA is the most widely studied of these tests and it has shown acceptable performance in the primary diagnosis of H pylori infection but the accuracy in post-treatment setting and in special clinical situations (e.g. upper gastrointestinal hemorrhage, gastric surgery, PPI therapy) has been controversial[5-9]. The three stool antigen tests have rarely been compared in parallel in the same study. The differences in patient characteristics (e.g. peptic ulcer vs gastritis) and widely variable prevalence of H pylori in different studies make the comparisons between the tests difficult as the statistical parameters of the performance of the tests are often dependent on the prevalence of the infection.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.
Recently, we evaluated the three stool antigen tests in \( H\) pylori-positive patients before and after eradication therapy. In the present study we also included \( H\) pylori-negative individuals. \( H\) pylori infection in all the subjects was verified by serology and \( ^{13}\)C-UBT.

**MATERIALS AND METHODS**

**Subjects**

Adults were invited with a newspaper announcement to participate in the study. Exclusion criteria were antibiotic treatment during previous 2 mo; use of \( H_{2}\)-receptor antagonists, bismuth or proton pump inhibitor therapy during previous 2 wk; \( H\) pylori eradication therapy during previous 5 years; gastric surgery; chronic gastrointestinal diseases; contraindications to drugs used in the study; pregnancy or lactation. Study subjects were screened for \( H\) pylori infection with rapid whole-blood antibody tests (Pyloriset Screen II, Orion Diagnostica, Espoo, Finland, or Biocard Helicobacter pylori IgG, AniBiotech Ltd, Vantaa, Finland). The present study was subsidiary to another study investigating the efficacy of probiotics in the eradication therapy of \( H\) pylori. Therefore, allergy to fruit juice containing the probiotics also belonged to the exclusion criteria.

The population screened comprised 1 574 subjects. Positive results in screening were confirmed with UBT and an in-house ELISA-based serologic method. Of the 300 \( H\) pylori-positive subjects in screening, 196 were positive in both of the confirmatory tests, but 11 subjects met one of the exclusion criteria; thus 185 \( H\) pylori-positive subjects were included in the study (of the remaining 104 subjects positive in screening, 49 were negative in both of the confirmatory tests, and for the rest either no confirmatory tests were performed or the results were discordant). From the subjects with \( H\) pylori-negative test result in screening, 114 (randomly selected by a computer program SPSS 12.0) were invited to bring the specimens for the confirmatory tests and 97 subjects followed this invitation. For these \( H\) pylori-negative study subjects, the infection was excluded with both of the confirmatory tests. Thus, the final study population consisted of 282 subjects: 185 were \( H\) pylori positive and 97 negative. The median age of the subjects was 52 years, range 23-71 years. The median age of \( H\) pylori-positive subjects was 55 years (range 25-71 years) and of \( H\) pylori-negative subjects 43 years (range 23-64 years). In total there were 186 females and 96 males.

**\( H\) pylori eradication therapy**

A total of 185 \( H\) pylori-positive subjects received the same eradication therapy: amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 1 wk. Exclusion criteria for the therapy were penicillin allergy, prolonged QT-interval, and antifungal therapy for dermatophyte infection.

**Serology**

At baseline and 4 mo after the end of eradication therapy the subjects gave serum samples for locally validated in-house ELISA. At baseline, serum samples had been investigated in order to confirm the infection, and they were stored at -20 °C until further used. Serum samples before and after eradication therapy were analyzed in parallel for both immunoglobulin G (IgG) and IgA antibodies as described earlier. \( H\) pylori eradication therapy was considered successful when antibody titers of at least IgG class had fallen 40% or more from the pretreatment level.

**UBT**

UBT was performed at baseline and 4 wk after the end of eradication therapy. Diabact tablets were used (Diabact UBT, Diabact AB, Uppsala, Sweden). After overnight fasting the subjects swallowed either one or two 50 mg Diabact tablets and blew into the test tube before and 10 min after ingesting the tablet(s). Results were analyzed by isotope ratio mass spectrometry (BreathMATPlus, Finnigan MAT GmbH, Bremen, Germany) and expressed as delta over baseline (DOB). Cut-off point for positive test result was DOB 2.2‰.

**Stool antigen tests**

All subjects gave stool specimens at baseline and those treated 4 wk after the end of eradication therapy. Stool specimens were stored at -20 °C before analysis and were thawed twice at most. Stool samples before and after therapy were always run in parallel in all three antigen tests.

The polyclonal antibody-based Premier Platinum HpSA test, later HpSA (Meridian Inc., Cincinnati, USA) was performed according to manufacturer’s instructions. Diluted stool specimens were added to the microtiter wells with a peroxidase-conjugated polyclonal antibody. After washing, substrate was added. The results were read at 450 nm by a spectrophotometry (Titertek Multiskan analyzer, Eflab Oy, Helsinki, Finland). Optical density (OD) values \(<0.140\) were negative, \(0.140-0.159\) equivocal (gray zone) and \(\geq0.160\) positive, as suggested by the manufacturer. In cases with gray zone values, the same stool samples stored at -20 °C were retested as recommended.

For the mAb-based Amplified IDEIA HpSTAR test, later HpSTAR (also known by name FemtoLab, Dako), the supernatant of stool suspension and peroxidase-conjugated mAbs were pipetted into the wells. After washing substrate was added, and the results were read by spectrophotometry. According to manufacturer’s instructions, OD values \(\geq0.190\) (450 nm) were assessed as positive and \(<0.190\) as negative.

ImmuCard STAT! HpSA-test, later Immunocard (Meridian Bioscience Europe) is based on monoclonal \( H\) pylori antibodies and a lateral flow chromatography technique. The diluted stool sample was dispensed to the sample port of the test cassette, and after incubation of 5 min at room temperature, the appearance of a pink-red line in the reading window indicated a positive result.

The Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the studies and all subjects.
RESULTS

The performance of the stool antigen tests at baseline is shown in Table 1 and after eradication therapy in Table 2. Four patients were treated with antimicrobials after eradication therapy before the 4 wk had elapsed and thus, stool specimens and UBTs of these particular patients were not collected until they gave the serum sample for serology 4 mo after the therapy. For all the other subjects, UBT was performed and stool specimens were collected 4 wk after therapy according to the study protocol.

The results after eradication therapy are presented for 182 subjects; 3 subjects had the results only at baseline. One patient died before the follow-up. Serum sample was collected and another subject discontinued the study during antimicrobial therapy because of severe headache, which later turned out to be viral meningitis as examined by a neurologist. After eradication therapy, the false-positive test results emphasizing the need for a confirmation of a positive UBT, serology and all three stool antigen tests but not confirmed negative also in the both confirmatory tests), the PPVs for all the three stool antigen tests were very high (94.0-97.8%) at baseline, and 96% and specificities between 82% and 94% in the primary diagnosis with sensitivities between 83% and 100% for HpSA and 87% and 100% for HpStAR in studies with high prevalence of H pylori infection[6,8,15-19] and are in line with the specificity of 96% in our present study population. ImmunoCard had a good sensitivity, 93.0%, but a low specificity, 88.7%, at baseline, leading to a high number of false-positive test results. In previous studies, ImmunoCard has shown variable results in the primary diagnosis with sensitivities between 83% and 96% and specificities between 82% and 94% [8,15,18-20].

The positive predictive values (PPVs) for all the three stool antigen tests were very high (94.0-97.8%) at baseline in our study population with a high prevalence (65.6%) of H pylori infection. Earlier the specificities of these tests have varied between 63% and 100% for HpSA and 87% and 100% for HpStAR in studies with high prevalence of H pylori infection [6,8,15-19] and are in line with the specificity of 96% in our present study population. ImmunoCard had a good sensitivity, 93.0%, but a low specificity, 88.7%, at baseline, leading to a high number of false-positive test results. In previous studies, ImmunoCard has shown variable results in the primary diagnosis with sensitivities between 83% and 96% and specificities between 82% and 94% [8,15,18-20].

The positive predictive values (PPVs) for all the three stool antigen tests were very high (94.0-97.8%) at baseline in our study population with a high prevalence (65.6%) of H pylori infection. However, if these stool antigen tests had been used to detect the infection in the original group of 1 574 screened study subjects with the prevalence of H pylori being 12% (in assuming that all the screened but not confirmed H pylori-negative subjects would have been negative also in the both confirmatory tests), the PPVs for these tests would have been only as follows: HpSA 76.6%, HpStAR 77.5%, and ImmunoCard 54.8%. It has been earlier suggested that at an H pylori prevalence of lower than 30%, the most cost effective diagnostic strategy would be to use stool antigen test and confirm positive results with UBT[4]. In our study, the ImmunoCard test had the lowest specificity and thus a high number of false-positive test results emphasizing the need for a confirmation of a
positive test result by UBT or serology.

In post-eradication setting, the position of these stool antigen tests is most controversial\(^7\). This is true especially for the most widely studied HpSA test, which also in our study showed a low sensitivity after eradication therapy. We had an exceptionally low eradication failure rate in this study, only 8.8%, and HpSA test was unable to find 19% of our eradication failures, which is in accordance with our previous endoscopy-based study, in which 25% of eradication failures were unidentified with this test\(^8\). For the HpStAR test, the sensitivity has varied after eradication therapy between 86% and 100%, specificity 95% and 100%, PPV 83% and 100%, and NPV 96% and 100%\(^9,10,18,39\). Our results fell well into this range. The performance of ImmunoCard after eradication therapy in the few published studies available has varied widely. In a study in adults ImmunoCard showed very low sensitivity both before (83%) and after (73%) eradication therapy but high specificity 98%\(^9\) whereas in the study of Gatta et al\(^1\) the sensitivity was 92% and specificity 100%. In our study all the three stool antigen tests had false-positive results in 2.5%-3.1% of successfully eradicated subjects, figures comparable with UBT\(^1,2,27\).

All patients except three in our study brought the follow-up UBT and stool specimens 4 wk after finishing the eradication therapy. In some previous studies using the HpSA test, it has been shown that the time elapsed after eradication therapy should not be less than 4 wk but extending the time beyond that would not clearly improve the results\(^3,6,12,19,29\). A positive HpSA test as early as 3 d after finishing eradication therapy has been highly predictive of eradication failure but a negative test result was reliable only after 3 wk\(^9\). Therefore, it is unlikely that after treatment a longer time before the collection of stool samples would have improved the results in our study.

In conclusion, in the primary diagnosis of H. pylori infection, the ELA-based HpSA and HpStAR stool antigen tests performed well. However, in a population with a lower prevalence of H. pylori infection, positive results even in these tests may be reasonable to confirm with UBT or serology. After eradication therapy, negative results were highly accurate for all the three tests and HpStAR even found all the subjects with an unsuccessful eradication. HpStAR had the best overall performance before and after eradication therapy.

ACKNOWLEDGMENTS

This study was in part presented at the XVI\(^{th}\) International Workshop, European Helicobacter Study Group, Vienna, Austria 24th September 2004. Our deepest appreciation goes to Pirjo Kosonen, Leena Seppo, Anu Kosonen, Minna Hietala, and Tiina Vikstedt for their skillful and assiduous assistance.

REFERENCES

1 Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon. 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
2 Fox JG, Wang TC. Helicobacter pylori—not a good bug after all! N Engl J Med 2001; 345: 829-32
3 Nakamura RM. Laboratory tests for the evaluation of Helicobacter pylori infections. J Clin Lab Anat 2001; 15: 301-307
4 Vakil N. Review article: the cost of diagnosing Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15 (Suppl 1): 10-15
5 Malferttheiner P, Mégraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
6 Vaira D, Ricci C, Menegatti M, Gatta L, Berardi S, Tampieri A, Miglioli M. Stool test for Helicobacter pylori. Am J Gastroenterol 2001; 96: 1935-1938
7 Parente F, Maconi G, Porro GB, Caselli M. Stool test with polyclonal antibodies for monitoring Helicobacter pylori infection in adults: a critical reappraisal. Scand J Gastroenterol 2002; 37: 747-749
8 Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9: 347-368
9 Hunt R, Fallone C, Veldhuyzen van Zanten S, Sherman P, Smaill F, Flook N, Thomson A. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori—an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004; 18: 547-554
10 Veijola L, Oksanen A, Löfgren T, Sipponen P, Karvonen AL, Rautelin H. Comparison of three stool antigen tests in confirming Helicobacter pylori eradication in adults. Scand J Gastroenterol 2005; 40: 395-401
11 Rautelin H, Kosunen TU. Helicobacter pylori infection in Finland. Ann Med 2004; 36: 82-88
12 Oksanen A, Veijola L, Sipponen P, Schauman KO, Rautelin H. Evaluation of Pyloriset Screen, a rapid whole-blood diagnostic test for Helicobacter pylori infection. J Clin Microbiol 1998; 36: 955-957
13 Pettersson A, Rasmussen M, Kyörönpalo S, Sipponen P, Rautelin H, Färläkä M, Oksanen A. A 10 minutes tablet based 13C-Urea breath test for the diagnosis of Helicobacter pylori. Gastroenterology 2001; 120 (Suppl 1): A579
14 Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, Miglioli M, Vaira D. A rapid, low-dose, 13C-urea tablet for the detection of Helicobacter pylori infection before and after treatment. Aliment Pharmacol Ther 2003; 17: 793-798
15 Agha-Amiri K, Peitz U, Mainz D, Kahls S, Leodolter A, Malferttheiner P. A novel immunoassay based on monoclonal antibodies for the detection of Helicobacter pylori antigens in human stool. Z Gastroenterol 2001; 39: 555-560
16 Andrews J, Marsden B, Brown D, Wong VS, Wood E, Kelsey M. Comparison of three stool antigen tests for Helicobacter pylori detection. J Clin Pathol 2003; 56: 769-771
17 Koletzko S, Konstantopoulos N, Bosman D, Feydt-Schmidt A, van der Ende A, Kalach N, Raymond J, Rüssmann H. Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter pylori antigen in stool from children. Gut 2003; 52: 804-806
18 Leodolter A, Peitz U, Ebert MP, Agha-Amiri K, Malferttheiner P. Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy. Am J Gastroenterol 2002; 97: 1682-1686
19 Makristathis A, Barouchs W, Pasching E, Binder C, Kuderna C, Apfalter P, Rotter ML, Hirschl AM. Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication therapy. J Clin Microbiol 2000; 38: 3710-3714
20 Chisholm SA, Watson CL, Teale EL, Saverymuttu S, Owen RJ. Non-invasive diagnosis of Helicobacter pylori infection in adult dyspeptic patients by stool antigen detection: does the
rapid immunochromatography test provide a reliable alternative to conventional ELISA kits? J Med Microbiol 2004; 53: 623-627

21 Gatta L, Perna F, Ricci C, Osborn JF, Tampieri A, Bernabucci V, Miglioli M, Vaira D. A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Aliment Pharmacol Ther 2004; 20: 469-474

22 Wu IC, Ke HL, Lo YC, Yang YC, Chuang CH, Yu FJ, Lee YC, Jan CM, Wang WM, Wu DC. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 2003; 50: 1761-1765

23 Leodolter A, Wolle K, Peitz U, Schaffranke A, Wex T, Malfertheiner P. Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status. Diagn Microbiol Infect Dis 2004; 48: 145-147

24 Li YH, Guo H, Zhang PB, Zhao XY, Da SP. Clinical value of Helicobacter pylori stool antigen test, ImmunoCard STAT HpSA, for detecting H pylori infection. World J Gastroenterol 2004; 10: 913-914

25 Makristathis A, Hirschl AM, Lehours P, Mégraud F. Diagnosis of Helicobacter pylori infection. Helicobacter 2004; 9 (Suppl 1): 7-14

26 Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48: 287-289

27 Lerang F, Haug JB, Moum B, Mowinckel P, Berge T, Ragnhildstveit E, Bjorneklett A. Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Scand J Gastroenterol 1998; 33: 710-715

28 Odaka T, Yamaguchi T, Koyama H, Saisho H, Nomura F. Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. Am J Gastroenterol 2002; 97: 594-599

29 Vaira D, Vakil N, Menegatti M, van’t Hoff B, Ricci C, Gatta L, Gashbarrini G, Quina M, Pajares Garcia JM, van Der Ende A, van Der Hulst R, Anti M, Duarte C, Gisbert JP, Miglioli M, Tytgat G. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280-287